Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INSM NASDAQ:ONC NASDAQ:PCVX NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSMInsmed$101.57-3.3%$145.87$64.85▼$212.75$21.92B0.892.47 million shs3.23 million shsONCBeOne Medicines$314.61-0.8%$301.40$218.31▼$385.22$34.53B0.5252,646 shs64,705 shsPCVXVaxcyte$51.80+0.6%$58.41$28.64▼$65.00$7.49B1.31.38 million shs546,264 shsRVMDRevolution Medicines$142.56+0.0%$113.41$34.00▼$155.70$30.30B1.413.48 million shs543,811 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSMInsmed-23.15%-22.72%-35.38%-29.70%+54.30%ONCBeOne Medicines+1.17%+7.36%+4.34%-10.43%+36.49%PCVXVaxcyte-9.84%-10.06%-15.18%-8.32%+77.55%RVMDRevolution Medicines-5.67%-1.12%+48.00%+46.18%+278.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSMInsmed$101.57-3.3%$145.87$64.85▼$212.75$21.92B0.892.47 million shs3.23 million shsONCBeOne Medicines$314.61-0.8%$301.40$218.31▼$385.22$34.53B0.5252,646 shs64,705 shsPCVXVaxcyte$51.80+0.6%$58.41$28.64▼$65.00$7.49B1.31.38 million shs546,264 shsRVMDRevolution Medicines$142.56+0.0%$113.41$34.00▼$155.70$30.30B1.413.48 million shs543,811 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSMInsmed-23.15%-22.72%-35.38%-29.70%+54.30%ONCBeOne Medicines+1.17%+7.36%+4.34%-10.43%+36.49%PCVXVaxcyte-9.84%-10.06%-15.18%-8.32%+77.55%RVMDRevolution Medicines-5.67%-1.12%+48.00%+46.18%+278.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSMInsmed 3.00Buy$212.36109.09% UpsideONCBeOne Medicines 2.79Moderate Buy$391.0024.28% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0066.03% UpsideRVMDRevolution Medicines 3.10Buy$103.88-27.14% DownsideCurrent Analyst Ratings BreakdownLatest PCVX, ONC, RVMD, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$230.00 ➝ $226.005/8/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$177.00 ➝ $160.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.005/7/2026ONCBeOne Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$410.00 ➝ $420.005/7/2026RVMDRevolution Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$205.005/7/2026ONCBeOne Medicines BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $409.005/7/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$423.00 ➝ $425.005/7/2026ONCBeOne Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$411.00 ➝ $413.005/7/2026RVMDRevolution Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.005/7/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSMInsmed$606.42M36.15N/AN/A$3.46 per share29.35ONCBeOne Medicines$5.34B6.46$3.92 per share80.16$39.77 per share7.91PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ARVMDRevolution Medicines$11.58M2,617.15N/AN/A$8.44 per share16.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSMInsmed-$1.28B-$6.41N/A73.07N/A-210.54%-168.36%-57.33%N/AONCBeOne Medicines$286.93M$2.5270.4130.66N/A8.94%12.55%6.96%N/APCVXVaxcyte-$766.63M-$5.62N/AN/AN/AN/A-32.83%-29.95%N/ARVMDRevolution Medicines-$1.13B-$5.91N/AN/AN/AN/A-80.79%-58.49%N/ALatest PCVX, ONC, RVMD, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billion2/26/2026Q4 2025ONCBeOne Medicines$1.60$0.58-$1.02$0.58$1.45 billion$1.50 billion2/25/2026Q4 2025RVMDRevolution Medicines-$1.56-$1.86-$0.30-$1.86$3.89 millionN/A2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A2/19/2026Q4 2025INSMInsmed-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINSMInsmedN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSMInsmed0.763.833.54ONCBeOne Medicines0.223.413.08PCVXVaxcyteN/A7.917.91RVMDRevolution Medicines0.167.147.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSMInsmedN/AONCBeOne Medicines48.55%PCVXVaxcyte96.78%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipINSMInsmed2.10%ONCBeOne Medicines6.62%PCVXVaxcyte3.10%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSMInsmed1,664215.85 million211.32 millionOptionableONCBeOne Medicines12,000109.72 million102.46 millionN/APCVXVaxcyte160144.39 million139.91 millionOptionableRVMDRevolution Medicines250212.59 million195.16 millionOptionablePCVX, ONC, RVMD, and INSM HeadlinesRecent News About These CompaniesRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $172.00 at Piper SandlerMay 8 at 5:31 AM | americanbankingnews.comRevolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 ExpiryMay 8 at 2:11 AM | tipranks.comRevolution Medicines Signals Breakout With RAS WinsMay 7 at 9:51 PM | tipranks.comRoyal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00May 7 at 2:11 PM | marketbeat.comRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewMay 7 at 1:50 PM | zacks.comRevolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptMay 7 at 12:10 PM | seekingalpha.comRevolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Wedbush Analyst SaysMay 7 at 10:56 AM | marketbeat.comPiper Sandler Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock PriceMay 7 at 10:03 AM | marketbeat.comComerica Bank Sells 466,931 Shares of Revolution Medicines, Inc. $RVMDMay 7 at 3:46 AM | marketbeat.comRevolution Medicines Q1 Earnings Call HighlightsMay 7 at 1:11 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPSMay 6 at 8:40 PM | marketbeat.comRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerMay 6 at 6:00 PM | globenewswire.comPromising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effectsMay 6 at 5:01 PM | reuters.comRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressMay 6 at 4:02 PM | globenewswire.comRevolution Medicines, Inc. $RVMD Shares Sold by State of New Jersey Common Pension Fund DMay 5 at 5:31 AM | marketbeat.comRevolution Medicines (RVMD) to Release Quarterly Earnings on WednesdayMay 4, 2026 | americanbankingnews.comRevolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityMay 2, 2026 | insidermonkey.comRevolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This StockMay 2, 2026 | finance.yahoo.comJennison Associates LLC Takes $24.31 Million Position in Revolution Medicines, Inc. $RVMDMay 2, 2026 | marketbeat.comRevolution Medicines wins FDA nod to provide early access to cancer therapyMay 1, 2026 | seekingalpha.comUS FDA authorizes early access to Revolution's pancreatic cancer pillMay 1, 2026 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes | April 17, 2026Allbirds Exits Shoes, Pivots to AI With NewBird RebrandBy Leo Miller | April 21, 2026These 3 Country ETFs Are Big Beneficiaries of the Iran CeasefireBy Dan Schmidt | April 13, 2026Spotify’s Ad Slump Raises a Bigger Question Than You ThinkBy Chris Markoch | April 29, 2026Berkshire Bet Constellation Cuts Guidance: Why Shares Rose 8% By Leo Miller | April 10, 2026PCVX, ONC, RVMD, and INSM Company DescriptionsInsmed NASDAQ:INSM$101.56 -3.44 (-3.27%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.BeOne Medicines NASDAQ:ONC$314.61 -2.39 (-0.75%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Vaxcyte NASDAQ:PCVX$51.80 +0.32 (+0.62%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Revolution Medicines NASDAQ:RVMD$142.56 +0.05 (+0.03%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
